CASE/0217/06/24 - Complainant v Organon

Allegations about a leaflet

  • Case number
    CASE/0217/06/24
  • Complaint received
    25 June 2024
  • Completed
    23 June 2025
  • Appeal hearing
    No appeal
  • Applicable Code year
    2021
  • No breach Clause(s)
  • Additional sanctions

Case Summary

This case was in relation to a three-page leaflet produced by Organon titled “What are my contraceptive options?”. The complainant alleged that, by advertising the advantages of the implant as a contraceptive option, the leaflet constituted promotion of Organon’s Nexplanon (etonogestrel) implant to the public. The complainant also alleged that not discussing the risks of complication of insertion of the implant and the recurrence of thrombotic risks after insertion was misleading with regard to patient safety.

The outcome under the 2021 Code was:

No Breach of Clause 2

Requirement that activities or materials must not bring discredit upon, or reduce confidence in, the pharmaceutical industry

No Breach of Clause 5.1 (x2)

Requirement to maintain high standards at all times

No Breach of Clause 26.1

Requirement not to advertise prescription only medicines to the public

No Breach of Clause 26.2

Requirement that information about prescription only medicines which is made available to the public must be factual, balanced, must not raise unfounded hopes of successful treatment or encourage the public to ask their health professional to prescribe a specific prescription only medicine

This summary is not intended to be read in isolation.
For full details, please see the full case report below.